Skip to content

Corvus Pharmaceuticals, Inc.

CRVS

CIK 0001626971

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$16.65M
+75.5% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.50
+48.0% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$32.08M
Q1 May 2026
Cash
$40.1M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
84.09M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings